Turmeric and Curcumin: What the Evidence Supports, and the Liver Risk Regulators Now Flag

Turmeric shows up in curry powder, golden lattes, and now in capsules promising everything from joint relief to a calmer gut. The spice itself has a long safety record in cooking. The concentrated capsules sold as "high-absorption" curcumin are a different story, and regulators in New Zealand and Australia have both flagged real, if rare, risks tied to that concentrated form. This guide separates what turmeric and curcumin can plausibly do from what the label is actually promising, and walks through the New Zealand rules that apply before you add a bottle to your cart.

What turmeric and curcumin actually are

Turmeric is the dried, ground rhizome of Curcuma longa, a plant in the ginger family grown mainly in India and Southeast Asia. It has coloured food and treated minor ailments in Ayurvedic, Chinese, and Thai traditional medicine for centuries. Curcumin is the best-known of the curcuminoid compounds that give turmeric its yellow colour, and it is usually the ingredient targeted in supplement marketing, even though whole turmeric contains far more than curcumin alone.

The US National Center for Complementary and Integrative Health (NCCIH) notes that curcumin typically makes up somewhere between 2 and 9 percent of turmeric powder by weight, which already explains why a teaspoon of curry spice and a 500 mg curcumin capsule are not comparable exposures. The NCBI Bookshelf's LiverTox reference puts curcumin content of whole turmeric extracts at roughly 1 to 6 percent by dry weight, with the rest made up of starch, fibre, fats, proteins, vitamins, minerals, and water. Either figure tells the same story: culinary turmeric delivers a modest, diluted dose, while a supplement is engineered to deliver curcumin in a concentrated, isolated form.

That distinction matters for everything that follows in this guide, because most of the evidence for benefit and nearly all of the safety concern attaches to the concentrated capsule form, not to curry.

Historically, turmeric's reputation rested on centuries of traditional use rather than controlled trials. Ayurvedic and traditional Chinese medicine systems used it for indigestion, colds, skin infections, arthritis, and liver complaints long before a modern lab isolated curcumin as the presumed active ingredient. That long record of dietary use is part of why turmeric is treated as generally recognised as safe when eaten as food, and it is a genuinely different safety question from what happens when the same compound is extracted, concentrated, and engineered to absorb faster than nature designed it to.

The bioavailability problem manufacturers are trying to solve

Plain curcumin has a well-documented absorption problem. It is poorly soluble in water, gets broken down quickly by the liver and gut wall, and is largely eliminated before it reaches meaningful blood levels. A widely cited pharmacokinetic review in the AAPS Journal, summarised on NCBI's PubMed Central archive, describes curcumin as having "poor absorption, biodistribution, metabolism, and bioavailability" in its natural state, which is exactly why supplement brands compete so hard on delivery technology.

The most common fix is adding piperine, the pungent compound in black pepper, sold under trademarked names like BioPerine. Piperine slows the liver enzymes that would otherwise clear curcumin quickly, which raises measured blood levels in short human trials. Other manufacturers use lipid-based carriers, phospholipid complexes, or nanoparticle formulations to the same end. These approaches genuinely increase how much curcumin reaches circulation. What they do not do is guarantee that the extra absorbed curcumin produces a proportionally larger benefit, and, as the next two sections cover, higher absorption is also the variable regulators now link to a rare but serious safety signal.

None of this is settled science. A 2020 pharmacokinetic summary noted that even with piperine, curcumin blood levels remain low compared with typical pharmaceutical drugs, and researchers still debate how much of the measured increase actually reaches joint or liver tissue rather than simply circulating briefly in plasma. Buyers should treat "20 times more bioavailable" marketing language as a claim about blood concentration in a small trial, not a guarantee of proportionally greater benefit or of safety equivalence with plain turmeric powder.

What the evidence actually supports for joint pain

Osteoarthritis is where curcumin has the largest and most consistent trial base. NCCIH's April 2025 review states plainly that "several meta-analyses have evaluated oral turmeric or curcumin for osteoarthritis measures related to relieving knee pain and stiffness," and describes the initial evidence as positive while stressing that higher-quality evidence is still needed to reach a firm conclusion. A 2022 systematic review and meta-analysis in BMC Complementary Medicine and Therapies (Feng et al.) pooled randomised trials of curcuminoids alone against placebo for knee osteoarthritis and reported measurable improvement in pain and function scores, though the authors flagged inconsistent dosing and formulation across the included studies as a limitation on how confidently the results generalise.

A separate 2021 meta-analysis comparing high-dose and low-dose curcumin regimens for knee osteoarthritis found that higher doses produced larger pain reductions, which is consistent with a genuine, dose-related effect rather than a placebo artefact alone. None of this evidence establishes curcumin as a replacement for standard osteoarthritis care such as weight management, physiotherapy, or prescribed anti-inflammatory medication; the trials mostly test it as an add-on over 8 to 12 weeks, not as a long-term standalone therapy.

Quality-of-evidence ratings matter as much as the headline result. A related meta-analysis comparing curcumin and Boswellia extracts for knee osteoarthritis, published in Cartilage, rated the overall quality of evidence for pain outcomes as "very low," citing high risk of bias in the underlying trials, moderate heterogeneity, and imprecise effect estimates. That rating does not mean curcumin does nothing for joint pain; it means the current body of trials is not yet strong enough to say with confidence how large or reliable the effect really is across different populations, doses, and formulations. Anyone reading a headline that says curcumin "beats ibuprofen" for arthritis pain, a comparison that has circulated from a single small trial, should treat it as one data point inside a much shakier overall evidence base, not as a settled finding.

Where the evidence is thinner: liver fat, mucositis, and everything else

Beyond joints, the picture gets noticeably weaker. NCCIH's assessment of turmeric and curcumin for nonalcoholic fatty liver disease (NAFLD) is that "initial research suggests" some liver-fat measures might improve, but which specific measures respond consistently is still unclear. Several meta-analyses reach broadly similar hedged conclusions: modest signal, high study heterogeneity, and a need for larger, better-controlled trials before the finding can be treated as settled.

Curcumin mouth rinses and capsules have also been studied for oral mucositis, the painful mouth and throat inflammation that can follow radiotherapy or chemotherapy for head and neck cancer. Several small randomised trials, summarised in a 2024 systematic review in Frontiers in Pharmacology, suggest a possible reduction in mucositis severity, but the trials are small, methods vary widely, and NCCIH's overall verdict for most other claimed uses, including depression, allergies, itching, and high cholesterol, is that there simply is not enough evidence to draw a definitive conclusion either way. Marketing copy that promises curcumin will meaningfully treat any of those conditions is running well ahead of what the cited trials can support.

Cardiovascular claims deserve a specific mention because they show up so often on New Zealand supplement shelves. Some small trials have measured modest reductions in LDL cholesterol or markers of vascular inflammation with curcumin supplementation, but sample sizes are typically under 100 participants, follow-up rarely exceeds three months, and results are inconsistent between trials that use different curcumin formulations. NCCIH's assessment folds these into the broader "not enough evidence to definitively conclude" category rather than treating them as an established benefit, and no major cardiology body currently recommends curcumin supplementation as a cholesterol-lowering strategy in place of diet, exercise, or prescribed medication.

The liver injury signal regulators are now tracking

This is the section that changed how health agencies talk about curcumin supplements. The Australian Therapeutic Goods Administration (TGA) completed a formal safety investigation and, as of its October 2023 update, had logged 18 reports of liver problems in people taking turmeric or curcumin products, with nine assessed as having enough detail to suggest the product caused the injury. Four of those nine had no other ingredient likely to be responsible; two were severe, including one fatal case. The TGA's conclusion is specific: "the risk of liver injury from taking Curcuma longa (turmeric) and/or curcumin in medicinal dosage forms" is rare but real, and "may be higher for products with enhanced absorption or bioavailability and/or higher doses."

Highly bioavailable formulations of curcumin, which enhance the body's ability to absorb the curcumin, may harm your liver. — National Center for Complementary and Integrative Health (NCCIH), April 2025

NCBI's LiverTox reference, last updated June 2025, goes further into the mechanism. It reports that turmeric has become "the most common cause of clinically apparent, herbal-related liver injury in the United States" among case series it tracks, with injury linked mainly, though not exclusively, to high-bioavailability curcumin products. Onset is typically insidious: fatigue, nausea, and poor appetite over one to four months, followed by dark urine and jaundice if the product is continued. LiverTox also flags a genetic clue: over 70 percent of documented turmeric-injury cases carried the HLA-B*35:01 allele, versus roughly 10 to 15 percent of the general population, suggesting an immune-mediated mechanism in susceptible individuals rather than a universal dose-toxicity relationship.

LiverTox estimates the overall incidence of clinically apparent liver injury from turmeric at somewhere between 1 in 10,000 and 1 in 100,000 people exposed. That is a small absolute risk. It is also why both TGA and NCCIH now recommend stopping the product immediately, not waiting it out, if symptoms such as yellowing skin or eyes, dark urine, unusual fatigue, or abdominal pain appear.

One documented case from LiverTox illustrates the pattern well. A 57-year-old woman with no prior liver disease started an over-the-counter turmeric product at 500 mg once daily. Two to three weeks later she developed fatigue, nausea, abdominal pain, and progressive jaundice, and blood tests on admission showed her liver enzymes (ALT and AST) more than twenty-five times the upper limit of normal. She had no viral hepatitis and had not started any other new medicine capable of explaining the injury. After stopping turmeric, her liver tests returned to normal within roughly three months, and a follow-up a year later showed no lasting damage. That recovery trajectory, rapid improvement after stopping the product, is typical of the cases LiverTox has catalogued, which is precisely why prompt recognition and discontinuation matter more than any specific treatment.

What Medsafe has said about turmeric in New Zealand

New Zealand's Medsafe issued its own monitoring communication on turmeric and curcumin products back in April 2018, though it centred on a different mechanism: drug interaction rather than direct liver toxicity. The Centre for Adverse Reaction Monitoring (CARM) received a case report of a patient on warfarin whose International Normalised Ratio (INR), a measure of blood clotting time, rose above 10 within weeks of starting a turmeric-containing product. An INR that high carries a real risk of serious bleeding.

Medsafe's advisory explains that curcumin has documented antiplatelet and NSAID-like anti-inflammatory effects, both of which can plausibly add to the blood-thinning action of warfarin, other anticoagulants, antiplatelet drugs, and even some SSRIs. The advisory does not ban turmeric or curcumin products in New Zealand; it tells consumers on any medicine that affects bleeding to check ingredient labels and talk to a pharmacist or doctor before adding a turmeric supplement. Notably, Medsafe's warning explicitly does not apply to turmeric used as a cooking spice, only to concentrated supplement products.

Medsafe's advisory sits inside a wider pattern: it is a monitoring communication, not a product recall or a change in legal status. Medsafe continues to accept adverse reaction reports about turmeric and curcumin products through CARM, and the agency has stated it continues monitoring the ingredient rather than having closed the file. That distinction matters for how seriously to take the warning: it is not evidence the risk has gone away, and it is not evidence the risk has grown large enough to justify removing the product category from sale. It is an active watch, and consumers on interacting medicines are the ones asked to act on it now rather than wait for a stronger signal.

How New Zealand actually regulates the product on the shelf

Unlike prescription medicines, dietary supplements containing turmeric or curcumin in New Zealand do not go through a pre-market approval process. Medsafe's dietary supplements guidance, last revised in October 2024, is direct about this: products are regulated under the Dietary Supplements Regulations 1985, which sit under the Food Act 2014, and "there is no pre-approval process for dietary supplements." Responsibility for safety, quality, and legal compliance sits with the sponsor, the company that puts the product on the market, not with a government reviewer checking each formula before it ships.

Medsafe administers labelling rules and maximum permitted daily doses for certain vitamins and minerals under those regulations, while the Ministry for Primary Industries oversees the wider Food Act framework the regulations sit inside. In practice, that means a turmeric capsule can legally reach a New Zealand shelf with an enhanced-bioavailability formulation and a joint-health claim without any regulator having tested that specific product for the liver-injury risk described above. The label review that happens is largely about lawful claims and required information, not a safety trial.

This is a lighter-touch model than the medicines pathway. A prescription or over-the-counter medicine sold in New Zealand goes through a formal assessment of quality, safety, and efficacy before Medsafe grants approval. A dietary supplement does not; the sponsor self-certifies compliance, and Medsafe's role is largely reactive, responding to CARM adverse-reaction reports, monitoring communications like the 2018 warfarin alert, and enforcement against unlawful claims after a product is already on sale. That gap is not unique to turmeric. It applies to the broader dietary supplement category in New Zealand, and it is one reason the same evidence-and-caution approach used in this guide, checking primary sources rather than trusting a label claim at face value, applies just as well to other ingredient categories covered elsewhere in this newsroom.

Reading a turmeric or curcumin label properly

A few checks make the difference between an informed purchase and a guess:

1. Curcumin dose. Check whether the label lists plain turmeric extract, isolated curcumin, or curcuminoids, and note the milligram dose. Products vary enormously, and some marketing copy quotes the turmeric weight rather than the actual curcumin content, which inflates the apparent dose.
2. Bioavailability enhancer. Look for piperine or a lipid/phospholipid carrier in the ingredients list. That single line tells you whether the product falls into the higher-absorption category that TGA and NCCIH now flag as carrying the greater, if still rare, liver risk.
3. Other active ingredients. Multi-ingredient joint or liver-support blends sometimes combine turmeric with other botanicals that carry their own hepatotoxicity profile, and TGA's case review found several liver-injury reports where another ingredient may have contributed alongside curcumin.
4. Warning statements. Note any label language about liver conditions, pregnancy, or medicine interactions. Their absence does not mean the product is risk-free under New Zealand's current approval pathway; it may just mean the sponsor has not been required to add one yet.

A practical way to compare products side by side is to write down four figures before buying: the curcumin (or curcuminoid) milligram dose per serving, whether a bioavailability enhancer is listed, the daily serving count needed to reach that dose, and the price per month at the labelled serving size. Comparing those four numbers across two or three brands usually reveals that the cheapest-looking bottle per unit is not always the cheapest per effective dose, and that some "clinically studied dose" claims on the front of the pack do not match the actual milligram figure printed on the back.

Who should be more cautious, and who should just talk to a pharmacist

People with current or past liver disease are the clearest higher-risk group. Both TGA and LiverTox recommend avoiding turmeric and curcumin supplements altogether if you have an existing or prior liver condition, given the documented cases of injury and the slow, insidious symptom onset that makes early self-detection hard. Anyone taking warfarin, another anticoagulant, an antiplatelet medicine, an NSAID, or an SSRI should raise a planned turmeric supplement with their prescriber first, in light of Medsafe's 2018 interaction warning; this is a conversation, not necessarily a hard stop, since dose and individual bleeding risk both matter.

Pregnant people should be cautious too. NCCIH notes that turmeric supplement use during pregnancy "may be unsafe," and that too little is known about high-dose use during breastfeeding to call it safe by default. None of these cautions apply to turmeric eaten as a spice in ordinary food amounts; every safety signal in this guide, from TGA's case reports to Medsafe's interaction warning, is specifically about concentrated supplement products, not curry.

Mild, non-serious side effects are far more common than the liver-injury signal and worth setting expectations around. NCCIH lists nausea, vomiting, acid reflux, stomach upset, diarrhoea, and constipation as the more typical oral side effects of turmeric or curcumin, alongside hives or itching from topical curcumin use. These are the reactions most people who try a turmeric supplement are actually likely to notice, and they generally resolve with a lower dose or stopping the product, without the same urgency attached to the rarer liver-injury symptoms covered earlier in this guide.

The bottom line before you buy

Turmeric's culinary use has centuries of safety behind it, and the trial evidence for curcumin in knee osteoarthritis is genuinely more promising than for most trendy supplement ingredients, particularly at higher, well-absorbed doses over several weeks. But "more promising" is not the same as proven, and the same formulation changes that make curcumin work better in a trial are the ones regulators now associate with rare liver injury. If you are otherwise healthy, not on blood-thinning or interacting medication, and want to try curcumin for joint symptoms, a moderate-dose, non-enhanced formulation used for a defined trial period, with attention to any new fatigue, nausea, or dark urine, is a more conservative starting point than the highest-absorption product on the shelf. If you have liver disease, take an anticoagulant, or are pregnant, the conversation belongs with a pharmacist or doctor before the bottle goes in the cart, not after.

Sources: National Center for Complementary and Integrative Health (NCCIH), "Turmeric" fact sheet, April 2025; Therapeutic Goods Administration (TGA), "Medicines containing turmeric or curcumin – risk of liver injury," October 2023; NCBI Bookshelf, LiverTox "Turmeric" record, June 2025; Medsafe New Zealand, "Beware turmeric/curcumin containing products can interact with warfarin," April 2018; Medsafe New Zealand, "Regulation of Dietary Supplements," October 2024; Feng J, Li Z, Tian L, et al., BMC Complementary Medicine and Therapies, 2022; Hsiao A-F, Lien Y-C, Tzeng I-S, et al., Complementary Therapies in Medicine, 2021.

Sources

www.nccih.nih.gov

www.tga.gov.au

www.ncbi.nlm.nih.gov

medsafe.govt.nz

www.medsafe.govt.nz

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

This article is for general education and does not replace advice from a qualified healthcare professional.